【Product for Licensing】siRNA Therapeutics Targeting INHBE and another target

Market Potential

1. Prevalence and Growing Demand for Obesity Treatment: Obesity has become a global epidemic, affecting about one billion people. It is projected that by 2035, if current trends continue, half of the world’s adults could be obese, with an estimated global economic impact exceeding $4 trillion. This increasing prevalence of obesity and demand for treatment present a significant market potential for siRNA products.
2. Innovativeness of siRNA Therapy: siRNA therapy offers an innovative approach to addressing obesity and related metabolic diseases. For instance, siRNA products targeting INHBE, such as WVE-007, are based on human genetics, where protective loss-of-function mutations in the INHBE gene are associated with healthier cardiometabolic traits, including less unhealthy visceral fat, lower triglycerides, and lower risks of type 2 diabetes and cardiovascular diseases.
3. Therapeutic Efficacy and Safety: siRNA therapy has shown weight loss effects similar to GLP-1 agonists in preclinical studies but with fewer side effects, including muscle loss. This combination of therapeutic efficacy and safety could increase the market appeal of siRNA products.

Competitive Landscape

1. Competitors and R&D Activities: Several biopharmaceutical companies and universities are researching siRNA products to treat obesity. Companies such as Wave Life Sciences, Regeneron, and Alnylam are protecting obese patients by silencing or reducing specific genes. This competitive activity indicates multiple players in the market, driving innovation in technology and therapeutic approaches.
2. Progress of INHBE-Targeting Products: Wave Life Sciences’ WVE-007, a GalNAc-siRNA targeting INHBE, plans to begin clinical trials in the first quarter of 2025. Arrowhead Pharmaceuticals has also announced preclinical data for ARO-INHBE and plans to apply for regulatory approval to begin clinical studies by the end of 2024. These advancements suggest that siRNA products targeting INHBE are at the forefront of competition.
3. Potential of Other Targets: In addition to INHBE, genome-wide association studies have identified about 250 genes associated with obesity. The diversity of these genes provides a broad range of potential targets for siRNA products, increasing market competitiveness and complexity.

In summary, siRNA products targeting INHBE and other targets show significant market potential for obese patients, while the competitive landscape is also continuously evolving with multiple companies actively advancing the development and clinical trials of related products. As these products further develop and potentially commercialize, siRNA therapy is expected to play an increasingly important role in the treatment of obesity and metabolic diseases.

If you are interested in this asset or need more information, please contact DrugTimes BD Team at BD@drugtimes.cn or visit our website at https://www.drugtimes.cn.